Rosacea News and Research

Latest Rosacea News and Research

Internet-based communication improves teenagers' use of topical acne therapy

Tech-savvy teens with acne used their medicine more frequently when they also took part in a web-based survey, a new study from Wake Forest Baptist Medical Center finds.

1 Nov 2011

Dermatologist discusses common skin conditions that affect people of color at AAD 2011 meeting

The U.S. Census Bureau predicts that by the year 2050, more than half the U.S. population will have skin of color. Recognizing this trend, dermatologists are educating the public about the different ways that common skin conditions appear in various skin tones.

5 Aug 2011

Stress management can improve chronic skin conditions

As anyone with a chronic, inflammatory skin condition, such as psoriasis, rosacea or acne, knows, dealing with unpredictable flares can cause considerable stress and have a negative impact on a person's overall well-being.

4 Aug 2011

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

As the baby boomer generation continues to increase in age, so does its passion to remain youthful, both inside and out. Beating the clock is now a multi-faceted, science-driven industry. From its age-old quests to find the elixir of life, to modern exploration of how microcellular activity contributes to metabolic breakdown, scientific research continues to advance its goals to enhance bodily energy, vigour and performance, and fade or stall the visible signs of aging.

16 Jun 2011

Non-laser light treatments may help treat common skin conditions

While dermatologists have used lasers successfully for years to treat common skin conditions such as acne, rosacea and aging skin, it now appears that even non-laser lights may provide some of the same benefits.

16 Mar 2011

MD Solarsciences launches new sunscreen lotion at 2011 AAD meeting

A year after its launch, the first dermatologist-driven company dedicated to primary skin cancer protection and prevention introduced its newest solar protection product -- a much-anticipated tinted mineral gel sunscreen – at the 2011 AAD meeting in New Orleans.

9 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Patients with acne and rosacea are often confused about selecting appropriate skin care products, cosmeceuticals and cosmetics to add into their daily routine. While they want to continue to see results with the treatment regimen from their dermatologist, they also want to be comfortable using products that address other skin issues, such as wrinkles or that protect their skin, such as sunscreens.

5 Feb 2011

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

Vicept Therapeutics, Inc. announced positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.

10 Jan 2011

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat).

10 Jan 2011

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Obagi Medical Products prices secondary offering

Obagi Medical Products, Inc., a leader in topical aesthetic and therapeutic skin health systems, today announced the pricing of the secondary public offering of 2,690,244 shares of its common stock by the Stonington Capital Appreciation 1994 Fund, L.P. and the Zein and Samar Obagi Family Trust, at a public offering price of $10.25 per share.

20 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.

20 Sep 2010

Quick-Med receives patent for MultiStat technology to treat Rosacea

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,795,302 entitled "Use of Compositions for Treating Rosacea."

15 Sep 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced positive results from a pharmacodynamic and pharmacokinetic clinical trial of the Company's lead product V-101, a topical cream under investigation for the treatment of erythema in patients with rosacea.

6 Aug 2010

Price of sun overindulgence and tanning misuse is not just skin deep

It's what marketers lead us to believe is the picture of glowing health - the ultimate tan. But sun overindulgence and tanning misuse does have a price. And it's not just skin deep.

28 Jul 2010

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

The June 2010 issue of Journal of Drugs in Dermatology (JDD), a full-color, peer-reviewed publication serving the dermatology community, features a study on the long-term efficacy and tolerability of the active ingredient in PyratineXR™.

16 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Rosacea News and Research

Latest Rosacea News and Research

Internet-based communication improves teenagers' use of topical acne therapy

Dermatologist discusses common skin conditions that affect people of color at AAD 2011 meeting

Stress management can improve chronic skin conditions

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

Non-laser light treatments may help treat common skin conditions

MD Solarsciences launches new sunscreen lotion at 2011 AAD meeting

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

Proper skin care, cosmetics can improve skin of acne and rosacea patients

Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea

KYTHERA and Intendis initiate ATX-101 European Phase III studies for reduction of submental fat

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

Obagi Medical Products prices secondary offering

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

NIAMS awards $684,000 SBIR grant to Signum Biosciences to develop GPCR modulating therapeutics

Quick-Med receives patent for MultiStat technology to treat Rosacea

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

V-101 shows safety profile in treating erythema of rosacea: Clinical study

Price of sun overindulgence and tanning misuse is not just skin deep

JDD publishes long-term efficacy and tolerability study of PyratineXR Moisturizing Lotion

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Rosacea News and Research

Latest Rosacea News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in